RPRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today, Repros Therapeutics Inc's share price is $7.19. Repros Therapeutics Inc's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2015 was $-0.32. Hence, Repros Therapeutics Inc's Price-to-Free-Cash-Flow Ratio for today is .
During the past 13 years, Repros Therapeutics Inc's highest Price-to-Free-Cash-Flow Ratio was 58.45. The lowest was 0.00. And the median was 45.60.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -100.00% per year.
During the past 13 years, Repros Therapeutics Inc's highest 3-Year average Free Cash Flow per Share Growth Rate was 68.70% per year. The lowest was 0.00% per year. And the median was -49.90% per year.
Repros Therapeutics Inc's Price-to-Free-Cash-Flow ratio for today is calculated as
|Price-to-Free-Cash-Flow Ratio||=||Share Price||/||Free Cash Flow per Share (TTM)|
Repros Therapeutics Inc's Share Price of today is $7.19.
Repros Therapeutics Inc's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2015 was -0.32 (Jun. 2014 ) + 0 (Sep. 2014 ) + 0 (Dec. 2014 ) + 0 (Mar. 2015 ) = $-0.32.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, managements decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Repros Therapeutics Inc Annual Data
Repros Therapeutics Inc Quarterly Data